EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
Open Access
- 18 April 2022
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 13 (1) , 1-10
Abstract
Adrenocortical carcinoma affects one in 5 million children each year. Since prognosis for children older than 4 years is limited, clinicians often choose aggressive treatment with etoposide, doxorubicin, cisplatin (EDP) and mitotane after resection. However, little is known about the impact of EDP-mitotane in children. We provide an overview of case-reports and case series listing side-effects and neurotoxicity of EDP-mitotane in children. Fourteen studies were identified describing a range of gastro-intestinal, endocrine, developmental and neuropsychological side-effects. Neurotoxicity included motor- and speech delay, decreased concentration and lower school performance. These side-effects appear to be reversible after mitotane discontinuation. We have added our own experience with a 10 year old girl with advanced adrenocortical carcinoma treated with EDP and 2 years of mitotane after irradical resection. She developed an impactful, but reversible, decrease in cognitive development measured by a standardized neuropsychological assessment before, during and after mitotane therapy. This decrease was mostly measurable in terms of decreased processing speed and concentration and a significant drop in school performance. Combined with fatigue and insecurity, this caused problems in short-term memory and the need to change her school type. In conclusion, EDP-mitotane is associated with several side-effects including neurotoxicity in pediatric cases, all reversible after mitotane discontinuation.Keywords
This publication has 42 references indexed in Scilit:
- Systemic Treatment of Adrenocortical Carcinoma in Children: Data from the German GPOH-MET 97 TrialKlinische Padiatrie, 2012
- Combination Chemotherapy in Advanced Adrenocortical CarcinomaNew England Journal of Medicine, 2012
- Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantlyEndocrine-Related Cancer, 2008
- Case Report: Adjuvant Therapy with a High Dose of Mitotane for Adrenocortical Carcinoma in a 4-year-old BoyClinical Pediatric Endocrinology, 2008
- Mitotane Associated With Cisplatin, Etoposide, and Doxorubicin in Advanced Childhood Adrenocortical CarcinomaJournal of Pediatric Hematology/Oncology, 2006
- Childhood adrenocortical tumoursEuropean Journal of Cancer, 2004
- Clinical and Outcome Characteristics of Children With Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor RegistryJournal of Clinical Oncology, 2004
- Adrenal Cortical Neoplasms in the Pediatric PopulationAmerican Journal of Surgical Pathology, 2003
- Reversible mental deterioration and neurological disturbances with o,p′-DDD therapyClinical Neurology and Neurosurgery, 1992
- Adrenocortical Carcinoma Treated with o,p'-DDDBMJ, 1965